Aleš Machara

Dr. Aleš Machara

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2018 in Viruses
Verified
Journal Article
Open access
PDF file
JPJana Pokorná
Jana Pokorná
PPPetr Pachl
Petr Pachl
EKElena Karlukova
Elena Karlukova
JHJakub Hejdánek
Jakub Hejdánek
Pavlína Maloy ŘezáčováPavlína Maloy Řezáčová
Pavlína Maloy Řezáčová
MKMilan Kožíšek
Milan Kožíšek
Neuraminidase is the main target for current influenza drugs. Reduced susceptibility to oseltamivir, the most widely prescribed neuraminidase inhibitor, has been repeatedly reported. The resistance substitutions I223V and S247N, alone or in combination with the major oseltamivir-resistance mutation H275Y, have been observed in 2009 pandemic H1N1 viruses. We overexpressed and purified the ectodomain of wild-type neuraminidase from the A/California/07/2009 (H1N1) influenza virus, as well as variants containing H275Y, I223V, and S247N single mutations and H275Y/I223V and H275Y/S247N double mutations. We performed enzymological and thermodynamic analyses and structurally examined the resistance mechanism. Our results reveal that the I223V or S247N substitution alone confers only a moderate reduction in oseltamivir affinity. In contrast, the major oseltamivir resistance mutation H275Y causes a significant decrease in the enzyme’s ability to bind this drug. Combination of H275Y with an I223V or S247N mutation results in extreme impairment of oseltamivir’s inhibition potency. Our structural analyses revealed that the H275Y substitution has a major effect on the oseltamivir binding pose within the active site while the influence of other studied mutations is much less prominent. Our crystal structures also helped explain the augmenting effect on resistance of combining H275Y with both substitutions.

1 July 2019 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
VZVáclav Zima
Václav Zima
CACarlos Berenguer Albiñana
Carlos Berenguer Albiñana
KRKateřina Rojíková
Kateřina Rojíková
JPJana Pokorná
Jana Pokorná
PPPetr Pachl
Petr Pachl
AMAleš Machara
Aleš Machara

1 December 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
VZVáclav Zima
Václav Zima
Katerina RadilovaKaterina Radilova
Katerina Radilova
MKMilan Kožíšek
Milan Kožíšek
CACarlos Berenguer Albiñana
Carlos Berenguer Albiñana
EKElena Karlukova
Elena Karlukova
AMAleš Machara
Aleš Machara
The biological effects of flavonoids on mammal cells are diverse, ranging from scavenging free radicals and anti-cancer activity to anti-influenza activity. Despite appreciable effort to understand the anti-influenza activity of flavonoids, there is no clear consensus about their precise mode-of-action at a cellular level. Here, we report the development and validation of a screening assay based on AlphaScreen technology and illustrate its application for determination of the inhibitory potency of a large set of polyols against PA N-terminal domain (PA-Nter) of influenza RNA-dependent RNA polymerase featuring endonuclease activity. The most potent inhibitors we identified were luteolin with an IC50 of 72 ± 2 nM and its 8-C-glucoside orientin with an IC50 of 43 ± 2 nM. Submicromolar inhibitors were also evaluated by an in vitro endonuclease activity assay using single-stranded DNA, and the results were in full agreement with data from the competitive AlphaScreen assay. Using X-ray crystallography, we analyzed structures of the PA-Nter in complex with luteolin at 2.0 Å resolution and quambalarine B at 2.5 Å resolution, which clearly revealed the binding pose of these polyols coordinated to two manganese ions in the endonuclease active site. Using two distinct assays along with the structural work, we have presumably identified and characterized the molecular mode-of-action of flavonoids in influenza-infected cells.

9 October 2018 in Journal of Natural Products
Verified
Journal Article
Closed access
AMAleš Machara
Aleš Machara
JKJan Křivánek
Jan Křivánek
KDKlára Dolejšová
Klára Dolejšová
JHJana Havlíčková
Jana Havlíčková
LBLucie Bednárová
Lucie Bednárová
PKPavlína Kyjaková
Pavlína Kyjaková

28 January 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JSJindrich Sedlacek
Jindrich Sedlacek
ZSZuzana Smahelova
Zuzana Smahelova
MAMichael Adamek
Michael Adamek
DSDominika Subova
Dominika Subova
LSLucie Svobodova
Lucie Svobodova
KSKlara Grantz Saskova
Klara Grantz Saskova
Intracellular protein aggregation causes proteotoxic stress, underlying highly debilitating neurodegenerative disorders in parallel with decreased proteasome activity. Nevertheless, under such stress conditions, the expression of proteasome subunits is upregulated by Nuclear Factor Erythroid 2-related factor 1 (NRF1), a transcription factor that is encoded by NFE2L1. Activating the NRF1 pathway could accordingly delay the onset of neurodegenerative and other disorders with impaired cell proteostasis. Here, we present a series of small-molecule compounds based on bis(phenylmethylen)cycloalkanones and their heterocyclic analogues, identified via targeted library screening, that can induce NRF1-dependent downstream events, such as proteasome synthesis, heat shock response, and autophagy, in both model cell lines and Caenorhabditis elegans strains. These compounds increase proteasome activity and decrease the size and number of protein aggregates without causing any cellular stress or inhibiting the ubiquitin-proteasome system (UPS). Therefore, our compounds represent a new promising therapeutic approach for various protein conformational diseases, including the most debilitating neurodegenerative diseases.

26 February 2016 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
AMAleš Machara
Aleš Machara
MEMary Ann A. Endoma‐Arias
Mary Ann A. Endoma‐Arias
ICIvana Císařová
Ivana Císařová
DCD. Phillip Cox
D. Phillip Cox
THTomas Hudlicky
Tomas Hudlicky